{"id":49119,"date":"2025-11-27T16:00:13","date_gmt":"2025-11-27T08:00:13","guid":{"rendered":"https:\/\/flcube.com\/?p=49119"},"modified":"2025-11-27T16:00:13","modified_gmt":"2025-11-27T08:00:13","slug":"innova-therapeutics-acquires-enci-therapeutics-ivt-8086-cancer-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49119","title":{"rendered":"Innova Therapeutics Acquires Enci Therapeutics&#8217; IVT-8086 Cancer Program"},"content":{"rendered":"\n<p><strong>Innova Therapeutics<\/strong> announced the acquisition of <strong>Enci Therapeutics<\/strong>, gaining its primary cancer therapeutic program <strong>IVT\u20118086<\/strong>, a first\u2011in\u2011class humanized monoclonal antibody targeting the <strong>SFRP2 pathway<\/strong>. Financial terms were not disclosed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-summary\">Transaction Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Innova Therapeutics<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Enci Therapeutics<\/td><\/tr><tr><td><strong>Asset Acquired<\/strong><\/td><td>IVT\u20118086 (first\u2011in\u2011class anti\u2011SFRP2 mAb)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Not disclosed<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>Completed November\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-ivt-8086\">Drug Profile \u2013 IVT\u20118086<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Humanized monoclonal antibody that <strong>antagonizes secreted Frizzled\u2011Related Protein 2 (SFRP2)<\/strong><\/li>\n\n\n\n<li><strong>Pathway:<\/strong> Blocks non\u2011canonical <strong>Wnt\/Ca\u00b2\u207a signaling<\/strong> cascade involved in angiogenesis, cell survival, proliferation, migration, invasion, tumorigenesis, and metastasis<\/li>\n\n\n\n<li><strong>Target Expression:<\/strong> SFRP2 is highly expressed in many <strong>solid and hematological malignancies<\/strong>, with expression levels correlating with patient prognosis<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Positioned for <strong>monotherapy and combination with immune checkpoint inhibitors (ICI)<\/strong> for various cancer types<\/li>\n\n\n\n<li><strong>Diagnostic Synergy:<\/strong> Companion diagnostic assay under development for <strong>early cancer detection, prognosis, and recurrence risk assessment<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Position:<\/strong> SFRP2 represents a <strong>novel, validated oncology target<\/strong> with no approved therapies globally<\/li>\n\n\n\n<li><strong>Broad Therapeutic Potential:<\/strong> Applicable across <strong>multiple tumor types<\/strong> given widespread SFRP2 expression<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Designed to <strong>enhance ICI efficacy<\/strong> by modulating tumor microenvironment<\/li>\n\n\n\n<li><strong>Integrated Biomarker:<\/strong> Diagnostic tool development supports <strong>precision medicine approach<\/strong> and commercial differentiation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Estimate<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Oncology Market<\/strong><\/td><td>$250\u202fbillion (2024)<\/td><td>Growing at 8% CAGR<\/td><\/tr><tr><td><strong>Targeted Therapy Segment<\/strong><\/td><td>$120\u202fbillion (2024)<\/td><td>High\u2011value niche<\/td><\/tr><tr><td><strong>SFRP2\u2011Expressing Cancers<\/strong><\/td><td>&gt;1\u202fmillion new cases annually<\/td><td>Across major tumor types<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>No approved SFRP2\u2011targeted therapies<\/strong> globally<\/td><td>First\u2011mover advantage<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td><strong>$500\u202fmillion\u20111\u202fbillion<\/strong><\/td><td>If successfully developed for multiple indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the acquisition, IVT\u20118086 development plans, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, regulatory approvals, competitive dynamics, and the company\u2019s ability to execute its development strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4478,2286],"class_list":["post-49119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-enci-therapeutics","tag-innovac-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innova Therapeutics Acquires Enci Therapeutics&#039; IVT-8086 Cancer Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49119\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innova Therapeutics Acquires Enci Therapeutics&#039; IVT-8086 Cancer Program\" \/>\n<meta property=\"og:description\" content=\"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49119\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T08:00:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innova Therapeutics Acquires Enci Therapeutics&#8217; IVT-8086 Cancer Program\",\"datePublished\":\"2025-11-27T08:00:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2703.webp\",\"keywords\":[\"Enci Therapeutics\",\"Innovac Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49119#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49119\",\"name\":\"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2703.webp\",\"datePublished\":\"2025-11-27T08:00:13+00:00\",\"description\":\"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49119\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49119#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innova Therapeutics Acquires Enci Therapeutics&#8217; IVT-8086 Cancer Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program - Insight, China&#039;s Pharmaceutical Industry","description":"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49119","og_locale":"en_US","og_type":"article","og_title":"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program","og_description":"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.","og_url":"https:\/\/flcube.com\/?p=49119","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T08:00:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49119#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49119"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innova Therapeutics Acquires Enci Therapeutics&#8217; IVT-8086 Cancer Program","datePublished":"2025-11-27T08:00:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49119"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","keywords":["Enci Therapeutics","Innovac Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49119#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49119","url":"https:\/\/flcube.com\/?p=49119","name":"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49119#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","datePublished":"2025-11-27T08:00:13+00:00","description":"Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT\u20118086, a first\u2011in\u2011class humanized monoclonal antibody targeting the SFRP2 pathway. Financial terms were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49119#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49119"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49119#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","width":1080,"height":608,"caption":"Innova Therapeutics Acquires Enci Therapeutics' IVT-8086 Cancer Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49119#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innova Therapeutics Acquires Enci Therapeutics&#8217; IVT-8086 Cancer Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49119"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49119\/revisions"}],"predecessor-version":[{"id":49121,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49119\/revisions\/49121"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49120"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}